KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Assets (2016 - 2025)

Amgen has reported Assets over the past 17 years, most recently at $90.6 billion for Q4 2025.

  • Quarterly results put Assets at $90.6 billion for Q4 2025, down 1.36% from a year ago — trailing twelve months through Dec 2025 was $90.6 billion (down 1.36% YoY), and the annual figure for FY2025 was $90.6 billion, down 1.36%.
  • Assets for Q4 2025 was $90.6 billion at Amgen, roughly flat from $90.1 billion in the prior quarter.
  • Over the last five years, Assets for AMGN hit a ceiling of $97.2 billion in Q4 2023 and a floor of $59.2 billion in Q1 2022.
  • Median Assets over the past 5 years was $89.0 billion (2023), compared with a mean of $79.4 billion.
  • Biggest five-year swings in Assets: dropped 8.06% in 2021 and later surged 52.24% in 2023.
  • Amgen's Assets stood at $61.2 billion in 2021, then rose by 6.47% to $65.1 billion in 2022, then soared by 49.19% to $97.2 billion in 2023, then fell by 5.47% to $91.8 billion in 2024, then dropped by 1.36% to $90.6 billion in 2025.
  • The last three reported values for Assets were $90.6 billion (Q4 2025), $90.1 billion (Q3 2025), and $87.9 billion (Q2 2025) per Business Quant data.